Guillem Pons-Lladó
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Guillem Pons-Lladó has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
Sandra Pujadas
Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona
3 shared publications- Albert C. van Rossum
Department of Cardiology, VU University Medical Centre, Amsterdam, The Netherlands
1 shared publication Alberto Hidalgo
Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona
1 shared publication- Alberto Hidalgo
Radiology Unit (HSCSP), Barcelona, Spain
1 shared publication - Anja Wagner
Comprehensive Cardiology of Stamford and Greenwich, Stamford, CT, USA
1 shared publication - Antoni Capdevila
Radiology Unit (HSCSP), Barcelona, Spain
1 shared publication
Latest Publications
- Open Access
- 9 March 2017
- Published by Springer Nature in Stem Cell Research & Therapy
- Vol. 8 (1) , 1-15
Allogenic adipose-derived stem cell therapy overcomes ischemia-induced microvessel rarefaction in the myocardium: systems biology study
Myocardial microvascular loss after myocardial infarction (MI) remains a therapeutic challenge. Autologous stem cell therapy was considered as an alternative; however, it has shown modest benefits due to the impairing effects of cardiovascular risk factors on stem cells. Allogenic adipose-derived stem cells (ASCs) may overcome such limitations, and because of their low immunogenicity and paracrine potential may be good candidates for cell therapy. In the present study we investigated the effects of allogenic ASCs and their released products on cardiac rarefaction post MI. Pig subcutaneous adipose tissue ASCs were isolated, expanded and GFP-labeled. ASC angiogenic function was assessed by the in-vivo chick chorioallantoic membrane (CAM) model. Pigs underwent MI induction and 7 days after were randomized to receive: allogenic ASCs (intracoronary infusion); conditioned media (CM; intravenous infusion); ASCs + CM; or PBS/placebo (control). Cardiac damage and function were monitored by 3-T cardiac magnetic resonance imaging upon infusion (baseline CMR) and 1 and 3 weeks thereafter. We assessed in the myocardium: microvessel density; angiogenic markers (CD105, CD31, TF, VEGFR2, VEGFR1, vWF, eNOS, CD62); collagen deposition; and reparative fibrosis (TGFβ/TβRII/collagen). Differential proteomics of ASCs and CM was performed to characterize the ASC protein signature. CAM indicated a significant ASC proangiogenic capacity. In pigs after MI, only PBS/placebo animals displayed an impaired cardiac function 3 weeks after infusion (p < 0.05 vs baseline). Administration of ASCs + CM significantly enhanced neovessel formation and favored cardiac repair post MI (p < 0.05 vs the other groups). Molecular markers of angiogenesis were significantly upregulated both at transcriptional and protein levels (p < 0.05). The in-silico bioinformatics analysis of the ASC and CM proteome (interactome) indicated activation of a coordinated protein network involved in the formation of microvessels and the resolution of rarefaction. Coadministration of allogenic ASCs and their CM synergistically contribute to the neovascularization of the infarcted myocardium through a coordinated upregulation of the proangiogenic protein interactome.
- 9 March 2017
- Published by Springer Nature in Stem Cell Research & Therapy
- Vol. 8 (1) , 1-15
Open AccessAllogenic adipose-derived stem cell therapy overcomes ischemia-induced microvessel rarefaction in the myocardium: systems biology study
Myocardial microvascular loss after myocardial infarction (MI) remains a therapeutic challenge. Autologous stem cell therapy was considered as an alternative; however, it has shown modest benefits due to the impairing effects of cardiovascular risk factors on stem cells. Allogenic adipose-derived stem cells (ASCs) may overcome such limitations, and because of their low immunogenicity and paracrine potential may be good candidates for cell therapy. In the present study we investigated the effects of allogenic ASCs and their released products on cardiac rarefaction post MI. Pig subcutaneous adipose tissue ASCs were isolated, expanded and GFP-labeled. ASC angiogenic function was assessed by the in-vivo chick chorioallantoic membrane (CAM) model. Pigs underwent MI induction and 7 days after were randomized to receive: allogenic ASCs (intracoronary infusion); conditioned media (CM; intravenous infusion); ASCs + CM; or PBS/placebo (control). Cardiac damage and function were monitored by 3-T cardiac magnetic resonance imaging upon infusion (baseline CMR) and 1 and 3 weeks thereafter. We assessed in the myocardium: microvessel density; angiogenic markers (CD105, CD31, TF, VEGFR2, VEGFR1, vWF, eNOS, CD62); collagen deposition; and reparative fibrosis (TGFβ/TβRII/collagen). Differential proteomics of ASCs and CM was performed to characterize the ASC protein signature. CAM indicated a significant ASC proangiogenic capacity. In pigs after MI, only PBS/placebo animals displayed an impaired cardiac function 3 weeks after infusion (p < 0.05 vs baseline). Administration of ASCs + CM significantly enhanced neovessel formation and favored cardiac repair post MI (p < 0.05 vs the other groups). Molecular markers of angiogenesis were significantly upregulated both at transcriptional and protein levels (p < 0.05). The in-silico bioinformatics analysis of the ASC and CM proteome (interactome) indicated activation of a coordinated protein network involved in the formation of microvessels and the resolution of rarefaction. Coadministration of allogenic ASCs and their CM synergistically contribute to the neovascularization of the infarcted myocardium through a coordinated upregulation of the proangiogenic protein interactome.
- 12 May 2016
- Published by Springer Nature
- p. 101-113
CMR Study Protocol for Valvular Diseases
- 12 May 2016
- Published by Springer Nature
- p. 1-32
Magnetic Resonance Sequences for Cardiovascular Applications and Study Planning
- 12 May 2016
- Published by Springer Nature
- p. 1-32
Magnetic Resonance Sequences for Cardiovascular Applications and Study Planning
- 12 May 2016
- Published by Springer Nature
- p. 49-69
CMR Study Protocol of Cardiomyopathies
- 12 May 2016
- Published by Springer Nature
- p. 93-100
CMR Study Protocol for Great Vessels
- 12 May 2016
- Published by Springer Nature
- p. 33-48
CMR Study Protocol of Ischemic Heart Disease
- 1 September 2014
- Published by Elsevier in Revista Española de Cardiología (English Edition)
- Vol. 67 (9) , 683-684
The Integral Nature of Cardiac Magnetic Resonance Imaging in the Work-up for Ischemic Heart Disease
- 1 September 2014
- Published by Elsevier in Revista Española de Cardiología (English Edition)
- Vol. 67 (9) , 683-684
The Integral Nature of Cardiac Magnetic Resonance Imaging in the Work-up for Ischemic Heart Disease
- Open Access
- 1 January 2009
- Published by Elsevier in Journal of Cardiovascular Magnetic Resonance
- Vol. 11 (1) , 43
Current variables, definitions and endpoints of the European Cardiovascular Magnetic Resonance Registry
- 1 January 2009
- Published by Elsevier in Journal of Cardiovascular Magnetic Resonance
- Vol. 11 (1) , 43
Open AccessCurrent variables, definitions and endpoints of the European Cardiovascular Magnetic Resonance Registry